Brilliant Violet 605™ anti-mouse CD19 Antibo
- 产品名称:
- Brilliant Violet 605™ anti-mouse CD19 Antibo
- 产品类别:
- 抗体
- 产品编号:
- 115539
- 产品应用:
- 115539
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Mouse CD19-expressing K562 human erythroleukemia cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
- Concentration
- ?g sizes: 0.2 mg/mL?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunofluorescence7.
- Application References
(PubMed link indicates BioLegend citation) -
- Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
- Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
- Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
- Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
- Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
- Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
- Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
- Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
- Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
- Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed
- Olive V, et al. 2013. Elife. 2:822. PubMed
- Miyai T, et al. 2014. PNAS. 111:11780. PubMed
- Product Citations
-
- Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
- Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
- Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
- Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
- Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
- Gawish R, et al. 2022. Elife. 11:. PubMed
- Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
- John S, et al. 2020. Sci Rep. 10:11377. PubMed
- Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed
- Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
- Benhamou D, et al. 2018. Front Immunol. 2.260416667. PubMed
- Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
- Maisonneuve C, et al. 2021. Cell Reports. 34(4):108677. PubMed
- Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
- van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
- Zhang R, et al. 2021. MAbs. 13:1904546. PubMed
- Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
- Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
- Hutter K, et al. 2020. FEBS J. . PubMed
- Li J, et al. 2018. Immunity. 49:178. PubMed
- Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
- Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
- Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
- White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed
- Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
- Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed
- Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
- Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
- Kitajima Y, et al. 2022. Cells. 11:. PubMed
- Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
- Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed
- Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
- Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
- Yousef H, et al. 2019. Nat Med. 25:988. PubMed
- Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
- Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
- Fedele C, et al. 2021. J Exp Med. 218: . PubMed
- Subramaniam N, et al. 2021. Blood Adv. 5:1259. PubMed
- Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
- Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
- Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
- Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed
- Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
- Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
- Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
- Bramwell K, et al. 2015. J Immunol. 195: 1647 - 1656. PubMed
- Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
- Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
- Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
- Nascimento DC, et al. 2021. Immunity. :. PubMed
- Laczkó D, et al. 2020. Immunity. 53:724. PubMed
- RRID
- AB_11203538 (BioLegend Cat. No. 115539) AB_2563067 (BioLegend Cat. No. 115540)
- Structure
- Ig superfamily, associates with CD21 and CD81, 95 kD
- Distribution
-
Pro-B cells to mature B cells (during development), follicular dendritic cells
- Function
- Modulates B cell activation and differentiation
- Ligand/Receptor
- CD21, CD81, Leu-13
- Cell Type
- B cells, Dendritic cells
- Biology Area
- Costimulatory Molecules, Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.
- Gene ID
- 12478 View all products for this Gene ID
- UniProt
- View information about CD19 on UniProt.org